Venture Capital

Latest Headlines

Latest Headlines

Fidelity, J&J back $27.5M round for U.K. respiratory startup

The U.K.'s Pulmocide has pulled down a $27.5 million Series A from a big-name cast of investors, setting out to discover and develop some inhaled drugs for viral and fungal respiratory infections.

Food allergy startup bags $17M for oral immunotherapy

California's fledgling Allergen Research Corp. has hauled in $17 million to get its oral peanut allergy immunotherapy through mid-stage trials, setting out ambitious goals to apply its platform to some of the world's most vexing food allergies.

Flagship Ventures launches a biotech on the human microbiome sea

After two years of building up its knowledge of the human microbiome, tiny Seres Health has emerged from stealth mode today with $10.5 million in venture cash from Flagship Ventures and a business plan to develop new therapies dubbed "Ecobiotics."

Argos rakes in $17.5M more to wrap up PhIII for cancer drug

Argos Therapeutics is working to get out from under the shadow of Dendreon and its disappointing Provenge, and now the North Carolina company has the cash it needs to get its kidney cancer candidate through Phase III and prove the promise of its dendritic cell platform.

Moderna nails $110M to get mRNA tech into the clinic

Moderna Therapeutics is having quite a year, and the Cambridge, MA, biotech just put a $110 million capstone on 2013, raising a colossal new round and riding high on technology that promises to transform the human body into a drug factory.

Billionaires bankroll Ganymed's $148M race through PhII cancer drug studies

The Strüngmann brothers' expensive taste for biotech companies has helped generate another big venture round for Ganymed Pharmaceuticals, a German biotech with claims to some cutting-edge cancer drug technology.

Pfizer joins Roche, GSK in $32M round for Mission Therapeutics

Pfizer's venture arm has chipped in to a $32 million venture round for Mission Therapeutics, a Cambridge, U.K.-based biotech developing deubiquitylating enzyme inhibitors. Existing investors Sofinnova Partners, Imperial Innovations, S.R. One (GlaxoSmithKline) and Roche Venture Fund also contributed to the round.

Big Pharma venture teams back Aileron's shift to early-stage R&D

Shifting more of its focus to clinical drug development, Cambridge, MA-based Aileron Therapeutics has rounded up $30 million in Series E cash to fund a Phase I/IIa study of its p53-targeted cancer drug candidate.

Catabasis nails $32.4M for triglyceride-busting drug

Cambridge, MA's Catabasis Pharmaceuticals has landed a $32.4 million Series B to advance its triglyceride-fighting drug, setting sights on a swelling market with a compound the company believes can outperform its competitors.

GeNO, uniQure look to leap through biotech IPO window in Q4 rush

Waltham, MA-based GeNO is looking to raise $50 million to back its work on a new, patient-friendly approach for delivering inhaled nitric oxide on the go. And a Dutch biotech, uniQure, is also positioning itself to go public after pioneering the world's first approved gene therapy.